IN8bio, Inc. Market Research Report

Background

Company Overview

IN8bio, Inc. is a clinical-stage biopharmaceutical company specializing in the development of gamma-delta T cell-based immunotherapies for the treatment of various cancers. Founded in 2016 and headquartered in New York City, the company operates its primary scientific operations in Birmingham, Alabama. IN8bio focuses on harnessing the unique properties of gamma-delta T cells to create innovative cancer therapies.

Mission and Vision

IN8bio's mission is to develop novel therapies that address cancer by leveraging the powerful and naturally occurring anti-cancer properties of gamma-delta T cells. The company aims to advance a pipeline of autologous, allogeneic, and genetically modified gamma-delta T cell therapies for both liquid and solid tumors.

Industry Significance

Gamma-delta T cells are a specialized subset of T cells with unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio's focus on these cells positions the company at the forefront of immuno-oncology, a rapidly evolving field with significant potential for developing targeted cancer therapies.

Key Strategic Focus

Core Objectives

IN8bio is dedicated to advancing its pipeline of gamma-delta T cell therapies, aiming to provide effective treatments for cancers with high unmet needs. The company's strategic focus includes:

Developing allogeneic, autologous, and genetically modified gamma-delta T cell therapies.

Conducting clinical trials to evaluate the safety and efficacy of these therapies in various cancer indications.

Establishing strategic partnerships to enhance research and development capabilities.

Areas of Specialization

IN8bio specializes in:

Gamma-delta T cell immunotherapies.

Cell therapy manufacturing and process development.

Clinical trial design and execution for oncology indications.

Key Technologies Utilized

The company employs its proprietary DeltEx platform, which utilizes:

Allogeneic gamma-delta T cells.

Autologous gamma-delta T cells.

Genetically modified gamma-delta T cells.

Primary Markets Targeted

IN8bio targets the following markets:

Oncology, focusing on both solid and liquid tumors.

Specifically, glioblastoma, acute myeloid leukemia (AML), and other hematologic malignancies.

Financials and Funding

Funding History

As of December 31, 2024, IN8bio has raised approximately $34.98 million across three funding rounds.

Recent Funding Rounds

Series C Round (September 2020): Raised $34.98 million.

Notable Investors

Specific details about individual investors are not publicly disclosed.

Utilization of Capital

The funds raised are primarily allocated towards:

Advancing clinical trials for lead product candidates.

Expanding research and development facilities.

Enhancing manufacturing capabilities.

Pipeline Development

Key Pipeline Candidates

INB-200: An autologous, genetically modified gamma-delta T cell therapy for newly diagnosed glioblastoma. Currently in Phase 1 clinical trials, with updated data presented at the 2024 Society for Neuro-Oncology Annual Meeting.

INB-100: An allogeneic gamma-delta T cell therapy for patients with acute myeloid leukemia undergoing hematopoietic stem cell transplantation. Phase 1 data presented at the 2025 Tandem Meetings.

INB-400: A company-sponsored Phase 2 clinical trial for newly diagnosed glioblastoma, initiated in the second half of 2023.

Stages of Clinical Trials

INB-200: Phase 1.

INB-100: Phase 1.

INB-400: Phase 2.

Target Conditions

Glioblastoma.

Acute myeloid leukemia.

Anticipated Milestones

INB-200: Completion of Phase 1 enrollment in 2023, with updated data expected later this year.

INB-100: Accelerating patient enrollment in the expansion cohort, aiming to complete enrollment in 2025.

INB-400: Initiation of Phase 2 clinical trial in the second half of 2023.

Technological Platform and Innovation

Proprietary Technologies

DeltEx Platform: A proprietary platform that employs allogeneic, autologous, and genetically modified gamma-delta T cells to develop cell therapies designed to effectively identify and eradicate tumor cells.

Significant Scientific Methods

Ex vivo expansion and activation of gamma-delta T cells.

Genetic engineering of gamma-delta T cells.

Cell-type specific manufacturing processes.

Leadership Team

Executive Profiles

William Ho: President, Chief Executive Officer, and Director. Co-founder of IN8bio, leading the company's strategic direction and operations.

Kate Rochlin, Ph.D.: Chief Operating Officer. Oversees the company's operational activities, including research and development, manufacturing, and clinical trials. Promoted to President and Chief Operating Officer in February 2026.

Patrick McCall, CPA: Chief Financial Officer. Manages the company's financial operations, including accounting, financial reporting, and investor relations.

Market and Competitor Analysis

Market Insights and Dynamics

The global cell therapy market was valued at approximately $6.88 billion in 2025 and is projected to reach $38.24 billion by 2034, growing at a compound annual growth rate (CAGR) of 21.05% from 2026 to 2034. North America held a dominant share of the global cell therapy market, accounting for 57.35% in 2025.

Competitor Overview

Adicet Bio, Inc. (ADCT): Develops allogeneic gamma-delta CAR-T therapies, combining CAR engineering with gamma-delta T cells.

TC Biopharm: Focuses on gamma-delta T cell therapies for cancer treatment.

Poseida Therapeutics: Engages in cell and gene therapies, including CAR-T cell therapies.

Strategic Collaborations and Partnerships

As of now, IN8bio has not publicly disclosed any strategic collaborations or partnerships.

Operational Insights

IN8bio's focus on gamma-delta T cell therapies differentiates it from competitors primarily developing CAR-T cell therapies. This unique approach may offer advantages in targeting solid tumors and reducing the risk of graft-versus-host disease in allogeneic settings.

Strategic Opportunities and Future Directions

IN8bio is well-positioned to capitalize on the growing interest in cell therapies by advancing its pipeline of gamma-delta T cell therapies. Future opportunities include expanding clinical trials, seeking strategic partnerships to enhance development capabilities, and exploring additional indications for its therapies.